Design Therapeutics Inc (DSGN) Stock Analysis

Design Therapeutics Inc (DSGN) is a publicly traded company in the HEALTHCARE sector. It trades at $10.17, carries a market capitalization of $654.55M. This page summarizes the public market data, fundamentals, and frequently asked questions for DSGN, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $10.17
• Market Cap: $654.55M
• EPS: $-1.20
• 52-Week High: $17.25
• 52-Week Low: $3.33

Market Sentiment

Design Therapeutics Inc currently has a Bullish sentiment score of 0.30.

About Design Therapeutics Inc

Design Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Carlsbad, California, dedicated to developing innovative therapies for degenerative disorders linked to nucleotide repeat expansions, including Friedreich's ataxia and other central nervous system diseases. The company is advancing a pipeline of proprietary small-molecule drug candidates designed to target the genetic causes of these conditions, aiming to restore normal cellular function and enhance patient outco...

GNG Research Analysis

GNG Research scores Design Therapeutics Inc (DSGN) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for DSGN.

Frequently Asked Questions

Does DSGN pay dividends?

Design Therapeutics Inc (DSGN) does not currently pay a regular dividend.

What is DSGN's market cap?

Design Therapeutics Inc (DSGN) has a market capitalization of $654.55M with a current stock price of $10.17.